Clopidogrel

FDA approves generic Plavix (clopidogrel) in a major after heart attack decision

king on a chess board As predicted in The Essential Guide to Prescription Drugs, 12 Top Meds for 2012, the FDA today approved the first generic form of Plavix (clopidogrel).

The Essential Guide to Prescription Drugs, A New Look at Plavix (clopidogrel)

EGPD on Plavix
$9.99

Will this medicine be going generic? Do the benefits outweigh the risks? Find out a wealth of important information in more than 40 categories. As usual, the Essential Guide helps you and your family with crucial herbal and prescription drug interactions, 12 important things to know if you take Plavix, tests to talk to your doctor about to follow up on treatment and even steps you can take to help get the most from this and other medicines. Includes where to find a free patient assistance program.

 

Comb-Bound Booklet.

$9.99

The Essential Guide to Prescription Drugs, A new and closer look at Aspirin

Essential Guide to Prescription Drugs - Asprin
$8.99

Would aspirin be a prescription drug if it came to market now? The editor thinks so and encourages you to not take this powerful medicine for granted. This is a new update to the book that started information on medicines and you don't need a PhD to understand it. Aspirin has serious benefit to risk questions for ongoing use for heart disease. This new booklet tells the latest information on aspirin, who gets the best results from it, tests you should talk to your doctor about, herbal medicines that contain aspirin but don't sound like they would, and much more.

$8.99

Rybacki's Recommendations from the American Heart Association meeting in Chicago

woman and anchor  Clinicians and patients are waiting for the anchor of uncertainty of medicines to be removed. While the AHA conference in Chicago isn't a panacea, it is (to paraphrase the AHA daily news) the center of cardiovascular medicine on the planet.

Members Only: 

woman and anchor  Clinicians and patients are waiting for the anchor of uncertainty of medicines to be removed. While the AHA conference in Chicago isn't a panacea, it is (to paraphrase the AHA daily news) the center of cardiovascular medicine on the planet.

Today I attended a session on Heart Failure which offered a great review of the physiology, treatments and pending research which will help people with failing hearts have a better quality of life and live longer with new proven medicines. Tomorrow will be a day to ASCEND HF as the results from that study are released. This will give us insight into the role of nesiritide (Natrecor) in heart failure (decompensated). I will tweet on this as rybackiknows on twitter tomorrow.

Hope springs eternal, but management by data from well-designed studies is the right way to go!   

The controversy around Natrecor stems from some research that broke in the last two years. As a first session of late breaking clinical trials, this study offers true hope for patients suffering from a failing heart pump.

In the same late breaking session, eplerenone (Inspra) and the EMPHASIS HF study will be revealed. Inspra is important because the study was suspended early after an interim peak showed that a SIGNIFICANT decrease in problems happened in the study group that got Inspra! More as the story unfolds... 

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.